Results for this period
Third quarter1 October 2025 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
An increase in the number of S-DSC® cell processing cases, a decrease in immune cell processing cases due to a decline in overseas patients, revenue recognized upon completion of technology transfers in the CDMO business, a decrease in revenue from facility operation and management fees, a review of the cost allocation method and reductions in the cost of sales, decreases in research and development expenses and selling, general and administrative expenses, and an increase in gains on the operation of investment partnerships.
Disclosure of material events, etc. is included. Although operating losses and negative operating cash flow have continued, the Company has determined that there is no material uncertainty regarding the going concern assumption. The notes on going concern state, “There are no applicable matters.”
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 October 2025 to 30 June 2026 |
| Net Sales | ¥609 million (YoY +6.5%) |
| Operating profit | ¥-929 million |
| Ordinary income | ¥-810 million |
| Profit attributable to owners of the parent | ¥-845 million |
| Net income per share | −¥3.11 |
| Equity ratio | End of the current fiscal period 89.4 / End of previous period 88.8 |
| Total assets | ¥3,785 million |
| Net assets | ¥3,393 million |
| Full-year earnings forecast | Net Sales ¥943 million (YoY +16.4%) / Operating profit ¥-1,454 million / Ordinary income ¥-1,449 million / Net income ¥-1,453 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Cell Processing Business ¥609,594 thousand (YoY +6.5%), Regenerative Medicine Products Business ¥295 thousand (YoY +44.3%) |
| Segment profit | Cell Processing Business ¥-252,854 thousand, Regenerative Medicine Products Business ¥-271,829 thousand |
| Depreciation and amortization | ¥72,748 thousand |
| Impairment loss | ¥33,160 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Loss on Investment Securities ¥33,160 thousand |
| Disclosure regarding the going concern assumption | Disclosure of material events, etc. is included. Although operating losses and negative operating cash flow have continued, the Company has determined that there is no material uncertainty regarding the going concern assumption. The notes on going concern state, “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 281,667,319 Shares |
| Treasury Shares at Period-End | 64 Shares |
| Factors Behind Changes in Business Performance | An increase in the number of S-DSC® cell processing cases, a decrease in immune cell processing cases due to a decline in overseas patients, revenue recognized upon completion of technology transfers in the CDMO business, a decrease in revenue from facility operation and management fees, a review of the cost allocation method and reductions in the cost of sales, decreases in research and development expenses and selling, general and administrative expenses, and an increase in gains on the operation of investment partnerships. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Losses narrowed due to the recognition of revenue related to technology transfers in the CDMO business, a review of the cost allocation method, efforts to reduce the cost of sales, decreases in research and development expenses and selling, general and administrative expenses, and an increase in gains on the operation of investment partnerships. At the same time, the number of immune cell processing cases declined due to a decrease in overseas patients, and revenue from facility operation and management fees also decreased.